ZVRA EBITDA | Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. (ZVRA) EBITDA

2026-06-30: Basis Reported; EBITDA $17.14M*; Operating income $16.78M; Depreciation and amortization $364.00K*.
2026-03-31: Basis Reported; EBITDA $52.51M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA $9.68M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $4.54M*; Operating income $4.14M; Depreciation and amortization $392.00K*.

Complete source-backed ebitda history.

Available history: 2013-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$17.14M*	$16.78M	$364.00K*	(m)	(m)	$217.00K*	$17.03M*	(m)	(m)	$16.56M	$4.04M
2026-03-31	Reported	$52.51M	(m)	(m)	(m)	144.99%	$35.00K	$6.14M	(m)	(m)	$20.78M	$6.91M
2025-12-31	Reported	$9.68M	(m)	(m)	(m)	28.36%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$4.54M*	$4.14M	$392.00K*	(m)	(m)	$554.00K*	$4.71M*	(m)	(m)	$16.93M	-$433.00K
2025-06-30	Reported	-$69.39M*	-$71.04M	$1.65M*	(m)	(m)	$213.00K*	-$3.60M*	(m)	(m)	$20.78M	$2.20M
2025-03-31	Reported	-$3.71M	(m)	(m)	(m)	-18.20%	$99.00K	-$8.22M	(m)	(m)	$19.55M	$1.18M
2024-12-31	Reported	-$13.77M	(m)	(m)	(m)	-114.32%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$25.69M*	-$27.31M	$1.62M*	(m)	(m)	$0.00*	-$18.14M*	(m)	(m)	$16.21M	$0.00
2024-06-30	Reported	-$22.23M*	-$23.80M	$1.56M*	(m)	(m)	$0.00*	-$19.11M*	(m)	(m)	$12.60M	$70.00K
2024-03-31	Reported	-$18.92M	(m)	(m)	(m)	-552.53%	$0.00	-$16.16M	(m)	(m)	$9.93M	-$70.00K
2023-12-31	Reported	-$14.37M	(m)	(m)	(m)	-111.22%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$15.30M*	-$15.36M	$62.00K*	(m)	(m)	$172.00K*	-$4.63M*	(m)	(m)	$5.82M	$177.00K
2023-06-30	Reported	-$6.17M*	-$6.25M	$78.00K*	(m)	(m)	$23.00K*	-$8.70M*	(m)	(m)	$6.61M	-$74.00K
2023-03-31	Reported	-$12.75M	(m)	(m)	(m)	-401.51%	$29.00K	-$4.04M	(m)	(m)	$7.23M	-$103.00K
2022-12-31	Reported	-$9.01M	(m)	(m)	(m)	-445.75%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$6.23M*	-$6.63M	$398.00K*	(m)	(m)	$28.00K*	-$6.60M*	(m)	(m)	$3.97M	-$33.00K
2022-06-30	Reported	-$24.59M*	-$24.77M	$181.00K*	(m)	(m)	$15.00K*	-$4.10M*	(m)	(m)	$3.56M	-$715.00K
2022-03-31	Reported	-$1.79M	(m)	(m)	(m)	-45.25%	$16.00K	-$3.55M	(m)	$3.08M	$2.73M	-$4.00K
2021-12-31	Reported	-$2.78M	(m)	(m)	(m)	-107.59%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$2.16M*	-$2.22M	$65.00K*	(m)	(m)	$4.00K*	-$2.73M*	(m)	$2.24M	(m)	$0.00
2021-06-30	Reported	$5.90M*	$5.83M	$64.00K*	(m)	(m)	$81.00K*	$16.60M*	(m)	$2.85M	(m)	$0.00
2021-03-31	Reported	$7.02M	(m)	(m)	(m)	57.97%	$0.00	-$2.59M	(m)	$2.27M	(m)	$0.00
2020-12-31	Reported	-$3.15M	(m)	(m)	(m)	-133.05%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$1.15M*	-$1.21M	$67.00K*	(m)	(m)	$0.00*	-$1.05M*	(m)	$1.71M	(m)	-$34.00K
2020-06-30	Reported	$2.66M*	$2.59M	$68.00K*	(m)	(m)	-$4.00K*	$2.19M*	(m)	$1.95M	(m)	$0.00
2020-03-31	Reported	-$3.7M	(m)	(m)	(m)	-177.26%	$11.00K	-$2.02M	(m)	$2.13M	(m)	(m)
2019-12-31	Reported	-$4.34M	(m)	(m)	(m)	-315.04%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	$3.31M*	$3.23M	$76.00K*	(m)	(m)	$4.00K*	-$2.23M*	$1.00M	$3.62M	(m)	$3.00K
2019-06-30	Reported	-$7.72M*	-$7.79M	$75.00K*	(m)	(m)	$0.00*	-$7.34M*	(m)	$4.80M	(m)	-$9.00K
2019-03-31	Reported	-$11.29M	(m)	(m)	(m)	(m)	$17.00K	-$11.07M	(m)	$8.53M	(m)	-$8.00K
2018-12-31	Reported	-$9.19M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$17.88M*	-$17.96M	$79.00K*	(m)	(m)	(m)	-$15.95M*	(m)	$13.33M	(m)	-$60.00K
2018-06-30	Reported	-$13.82M*	-$13.91M	$83.00K*	(m)	(m)	(m)	-$9.15M*	(m)	$10.49M	(m)	-$39.00K
2018-03-31	Reported	-$14.69M	(m)	(m)	(m)	(m)	(m)	-$14.10M	(m)	$11.64M	(m)	-$8.00K
2017-12-31	Reported	-$8.07M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$5.54M	(m)	-$31.00K
2017-09-30	Reported	-$9.53M*	-$9.61M	$87.00K*	(m)	(m)	$35.00K*	-$10.17M*	(m)	$6.29M	(m)	-$4.00K
2017-06-30	Reported	-$8.14M*	-$8.22M	$84.00K*	(m)	(m)	$44.00K*	-$6.47M*	(m)	$4.65M	(m)	-$4.00K
2017-03-31	Reported	-$7.3M	(m)	(m)	(m)	(m)	$99.00K	-$9.52M	(m)	$4.11M	(m)	-$4.00K
2016-12-31	Reported	-$10.76M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$7.96M	(m)	-$4.00K
2016-09-30	Reported	-$10.36M*	-$10.40M	$42.00K*	(m)	(m)	$335.00K*	(m)	(m)	$4.29M	(m)	-$19.00K
2016-06-30	Reported	-$9.25M*	-$9.28M	$29.00K*	(m)	(m)	$153.00K*	(m)	(m)	$4.99M	(m)	-$4.00K
2016-03-31	Reported	-$6.94M	(m)	(m)	(m)	(m)	$66.00K	(m)	(m)	$3.23M	(m)	$12.00K
2015-12-31	Reported	-$7.26M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$4.72M	(m)	-$1.00K
2015-09-30	Reported	-$6.46M*	-$6.48M	$21.00K*	(m)	(m)	$55.00K*	(m)	(m)	$4.33M	(m)	$20.00K
2015-06-30	Reported	-$5.94M*	-$5.96M	$20.00K*	(m)	(m)	$19.00K*	(m)	(m)	$2.77M	(m)	$0.00*
2015-03-31	Reported	-$3.08M	(m)	(m)	(m)	(m)	$21.00K	(m)	(m)	$2.12M	(m)	$7.00K
2014-12-31	Reported	-$7.47M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$5.91M	(m)	$27.00K
2014-09-30	Reported	-$4.32M*	-$4.34M	$18.00K*	(m)	(m)	$8.00K*	(m)	(m)	$3.25M	(m)	-$38.00K
2014-06-30	Reported	-$3.03M*	-$3.04M	$19.00K*	(m)	(m)	$7.00K*	(m)	(m)	$1.72M	(m)	-$6.00K
2014-03-31	Reported	-$1.55M	(m)	(m)	(m)	(m)	$4.00K	(m)	(m)	$1.04M	(m)	-$5.00K

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$58.89M	(m)	(m)	(m)	-55.31%	$835.00K	-$1.60M	(m)	(m)	$77.62M	$3.45M
2024-12-31	Reported	-$80.61M	(m)	(m)	(m)	-341.41%	$0.00	-$69.67M	(m)	(m)	$54.87M	$15.37M
2023-12-31	Reported	-$48.6M	(m)	(m)	(m)	-176.97%	$296.00K	-$33.53M	(m)	(m)	$34.31M	$0.00
2022-12-31	Reported	-$41.62M	(m)	(m)	(m)	-409.62%	$93.00K	-$18.72M	(m)	(m)	$15.04M	-$33.00K
2021-12-31	Reported	$7.99M	(m)	(m)	(m)	27.87%	$102.00K	$10.44M	(m)	$10.16M	(m)	$34.00K
2020-12-31	Reported	-$5.34M	(m)	(m)	(m)	-40.16%	$33.00K	-$1.94M	(m)	$8.84M	(m)	-$34.00K
2019-12-31	Reported	-$20.03M	(m)	(m)	(m)	-156.03%	$26.00K	-$23.74M	$10.00M	$19.41M	(m)	-$22.00K
2018-12-31	Reported	-$55.58M	(m)	(m)	(m)	(m)	$21.00K	-$54.20M	$0.00	$41.76M	(m)	-$126.00K
2018-09-30	Rolling	(m)	-$54.78M*	(m)	(m)	(m)	(m)	(m)	(m)	$40.99M*	(m)	-$138.00K*
2018-06-30	Rolling	(m)	-$46.44M*	(m)	(m)	(m)	(m)	(m)	(m)	$33.95M*	(m)	-$82.00K*
2018-03-31	Rolling	(m)	-$40.76M*	(m)	(m)	(m)	(m)	(m)	(m)	$28.12M*	(m)	-$47.00K*
2017-12-31	Reported	-$33.03M	(m)	(m)	(m)	(m)	$181.00K	-$33.10M	(m)	$20.59M	(m)	-$43.00K
2017-12-31	Rolling	(m)	-$33.37M*	(m)	(m)	(m)	(m)	(m)	(m)	$20.59M*	(m)	-$43.00K*
2017-09-30	Rolling	(m)	-$36.05M*	(m)	(m)	(m)	(m)	(m)	(m)	$23.02M*	(m)	-$16.00K*
2017-06-30	Rolling	(m)	-$36.84M*	(m)	(m)	(m)	(m)	(m)	(m)	$21.01M*	(m)	-$31.00K*
2017-03-31	Rolling	(m)	-$37.89M*	(m)	(m)	(m)	(m)	(m)	(m)	$21.35M*	(m)	-$31.00K*
2016-12-31	Reported	-$37.31M	(m)	(m)	(m)	(m)	$643.00K	-$29.77M	(m)	$20.47M	(m)	-$15.00K
2016-12-31	Rolling	(m)	-$37.48M*	(m)	(m)	(m)	(m)	(m)	(m)	$20.47M*	(m)	-$15.00K*
2016-09-30	Rolling	(m)	-$33.93M*	(m)	(m)	(m)	(m)	(m)	(m)	$17.23M*	(m)	-$12.00K*
2016-06-30	Rolling	(m)	-$30.01M*	(m)	(m)	(m)	(m)	(m)	(m)	$17.27M*	(m)	$27.00K*
2016-03-31	Rolling	(m)	-$26.69M*	(m)	(m)	(m)	(m)	(m)	(m)	$15.05M*	(m)	$31.00K*
2015-12-31	Reported	-$22.73M	(m)	(m)	(m)	(m)	$135.00K	-$20.27M	(m)	$13.93M	(m)	$26.00K
2015-12-31	Rolling	(m)	-$22.81M*	(m)	(m)	(m)	(m)	(m)	(m)	$13.93M*	(m)	$26.00K*
2015-09-30	Rolling	(m)	-$23.02M*	(m)	(m)	(m)	(m)	(m)	(m)	$15.13M*	(m)	$54.00K*
2015-06-30	Rolling	(m)	-$20.88M*	(m)	(m)	(m)	(m)	(m)	(m)	$14.05M*	(m)	-$4.00K*
2015-03-31	Rolling	(m)	-$17.97M*	(m)	(m)	(m)	(m)	(m)	(m)	$13.00M*	(m)	-$10.00K*
2014-12-31	Reported	-$16.37M	(m)	(m)	(m)	(m)	$47.00K	(m)	(m)	$11.92M	(m)	-$22.00K
2014-12-31	Rolling	(m)	-$16.44M*	(m)	(m)	(m)	(m)	(m)	(m)	$11.92M*	(m)	-$22.00K*
2013-12-31	Reported	-$4.65M	(m)	(m)	(m)	(m)	$51.00K	(m)	(m)	$3.37M	(m)	-$20.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Climb Bio, Inc. (CLYM)	United States	$0.683B	-13.03
BlossomHill Therapeutics, Inc. (BLSM)	United States	$0.647B
IRONWOOD PHARMACEUTICALS INC (IRWD)	United States	$0.694B	5.37
Shattuck Labs, Inc. (STTK)	United States	$0.634B	-13.30
Nuvectis Pharma, Inc. (NVCT)	United States	$0.705B	-17.53
Verastem, Inc. (VSTM)	United States	$0.706B	-1.71
Neurogene Inc. (NGNE)		$0.625B	-4.46
IMPACT BIOMEDICAL INC. (IBO)	United States	$0.611B	66.47
Aquestive Therapeutics, Inc. (AQST)	United States	$0.606B	-6.67
CorMedix Inc. (CRMD)	United States	$0.605B	3.25